Share Price and Basic Stock Data
Last Updated: December 5, 2025, 6:29 pm
| PEG Ratio | 2.21 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Jyothy Labs Ltd operates within the personal care industry, focusing on household products and personal care items. The company’s revenue has demonstrated a consistent upward trajectory, with sales reported at ₹2,486 Cr for the fiscal year ending March 2023, up from ₹2,196 Cr in March 2022. This growth reflects a compounded annual growth rate (CAGR) of approximately 13.2% over the last year. Quarterly sales figures reveal a robust performance, peaking at ₹732 Cr in September 2023, showcasing a significant year-on-year increase. The latest financial data for December 2023 indicated a slight decline in sales to ₹678 Cr, yet overall, the company’s revenue trend remains positive, with an expected annual revenue of ₹2,847 Cr by March 2025. This growth trajectory is supported by an expanding product portfolio and increased market penetration, which solidifies Jyothy Labs’ position in the competitive landscape of the personal care sector.
Profitability and Efficiency Metrics
Jyothy Labs has maintained strong profitability metrics, with a reported net profit of ₹370 Cr for the fiscal year ending March 2025, up from ₹240 Cr in March 2023. The company’s operating profit margin (OPM) stood at 18% for the latest fiscal year, indicating efficient cost management and operational effectiveness. The gross profit margin has also shown improvement, rising from 11% in March 2022 to 18% in March 2025. Efficiency ratios further highlight the company’s effectiveness; the return on equity (ROE) is recorded at 19%, while return on capital employed (ROCE) stands at a commendable 24.6%. The interest coverage ratio is notably high at 93.62x, reflecting the company’s ability to meet its interest obligations comfortably. These metrics underscore Jyothy Labs’ strong operational efficiency and effective financial management, positioning it favorably against sector averages.
Balance Sheet Strength and Financial Ratios
The balance sheet of Jyothy Labs exhibits considerable strength, with total assets amounting to ₹2,691 Cr as of March 2025. The company has reported reserves of ₹2,013 Cr, indicating a solid equity base. Notably, Jyothy Labs maintains minimal borrowings, with total borrowings reported at ₹61 Cr, which translates to a debt-to-equity ratio of 0.00, showcasing its low leverage and financial prudence. The current ratio is robust at 2.76, indicating strong liquidity, while the quick ratio stands at 2.12, ensuring that the company can cover its short-term liabilities efficiently. The price-to-book value (P/BV) ratio is recorded at 5.89x, which is relatively high compared to industry norms, suggesting that the stock may be overvalued in relation to its book value. Overall, the financial ratios reflect a stable and well-managed balance sheet, enhancing investor confidence.
Shareholding Pattern and Investor Confidence
Jyothy Labs’ shareholding structure indicates a strong commitment from promoters, holding 62.88% of the total shares. This stable promoter holding is essential for long-term strategic direction and reflects confidence in the company’s growth trajectory. Institutional investors hold a significant stake, with Foreign Institutional Investors (FIIs) at 12.11% and Domestic Institutional Investors (DIIs) at 16.08%, highlighting a diversified investor base. The number of shareholders has increased to 2,17,305, indicating growing retail interest in the stock. However, there has been a slight decline in FII participation from 16.43% in March 2024 to the current 12.11%, which could be a point of concern for potential investors. Despite this, the overall shareholding pattern suggests a robust level of confidence in Jyothy Labs’ operational and financial performance, essential for sustaining growth and market presence.
Outlook, Risks, and Final Insight
Looking ahead, Jyothy Labs is well-positioned to capitalize on the growing demand for personal care products, supported by its strong revenue growth and profitability metrics. However, potential risks include fluctuations in raw material costs and competitive pressures from established players within the personal care sector. Additionally, any adverse changes in consumer preferences could impact sales. The company’s ability to innovate and adapt to market trends will be crucial for sustaining its growth trajectory. If Jyothy Labs continues to enhance its product offerings and maintain operational efficiencies, it will likely navigate these challenges effectively. Conversely, failure to address these risks could hinder its performance. Overall, the company represents a compelling investment opportunity within the personal care industry, provided it can manage its operational and market risks effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Jyothy Labs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Honasa Consumer Ltd | 8,949 Cr. | 275 | 334/190 | 71.9 | 38.8 | 0.00 % | 7.44 % | 5.51 % | 10.0 |
| Ambica Agarbathies Aroma & Industries Ltd | 44.2 Cr. | 25.7 | 37.0/23.3 | 86.6 | 65.2 | 0.00 % | 7.49 % | 0.45 % | 10.0 |
| Ador Multi Products Ltd | 124 Cr. | 129 | 134/23.4 | 32.5 | 0.00 % | 11.4 % | 3.09 % | 10.0 | |
| Kaya Ltd | 576 Cr. | 378 | 488/204 | 60.9 | 0.00 % | 2.50 % | % | 10.0 | |
| Jyothy Labs Ltd | 10,649 Cr. | 290 | 433/268 | 29.1 | 55.8 | 1.21 % | 24.6 % | 19.0 % | 1.00 |
| Industry Average | 69,555.29 Cr | 1,898.19 | 57.15 | 112.70 | 0.75% | 29.21% | 23.91% | 4.94 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 547 | 597 | 659 | 613 | 617 | 687 | 732 | 678 | 660 | 742 | 734 | 704 | 667 |
| Expenses | 489 | 537 | 579 | 528 | 526 | 570 | 597 | 559 | 552 | 608 | 595 | 589 | 555 |
| Operating Profit | 57 | 60 | 80 | 84 | 91 | 117 | 135 | 119 | 108 | 133 | 138 | 116 | 112 |
| OPM % | 10% | 10% | 12% | 14% | 15% | 17% | 18% | 18% | 16% | 18% | 19% | 16% | 17% |
| Other Income | 6 | 13 | 12 | 15 | 6 | 17 | 13 | 11 | 13 | 14 | 13 | 14 | 11 |
| Interest | 3 | 3 | 3 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 15 | 13 | 13 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 14 | 14 | 15 |
| Profit before tax | 45 | 57 | 76 | 84 | 82 | 121 | 135 | 115 | 107 | 132 | 136 | 114 | 107 |
| Tax % | 17% | 16% | 14% | 20% | 28% | 21% | 23% | 21% | 27% | 23% | 23% | 23% | 29% |
| Net Profit | 37 | 48 | 65 | 67 | 59 | 96 | 104 | 91 | 78 | 102 | 105 | 87 | 76 |
| EPS in Rs | 1.03 | 1.32 | 1.76 | 1.84 | 1.61 | 2.62 | 2.84 | 2.48 | 2.13 | 2.77 | 2.86 | 2.38 | 2.08 |
Last Updated: May 31, 2025, 8:43 am
Below is a detailed analysis of the quarterly data for Jyothy Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 667.00 Cr.. The value appears to be declining and may need further review. It has decreased from 704.00 Cr. (Dec 2024) to 667.00 Cr., marking a decrease of 37.00 Cr..
- For Expenses, as of Mar 2025, the value is 555.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 589.00 Cr. (Dec 2024) to 555.00 Cr., marking a decrease of 34.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 112.00 Cr.. The value appears to be declining and may need further review. It has decreased from 116.00 Cr. (Dec 2024) to 112.00 Cr., marking a decrease of 4.00 Cr..
- For OPM %, as of Mar 2025, the value is 17.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Dec 2024) to 17.00%, marking an increase of 1.00%.
- For Other Income, as of Mar 2025, the value is 11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Dec 2024) to 11.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Mar 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Dec 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Mar 2025, the value is 15.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.00 Cr. (Dec 2024) to 15.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 107.00 Cr.. The value appears to be declining and may need further review. It has decreased from 114.00 Cr. (Dec 2024) to 107.00 Cr., marking a decrease of 7.00 Cr..
- For Tax %, as of Mar 2025, the value is 29.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Dec 2024) to 29.00%, marking an increase of 6.00%.
- For Net Profit, as of Mar 2025, the value is 76.00 Cr.. The value appears to be declining and may need further review. It has decreased from 87.00 Cr. (Dec 2024) to 76.00 Cr., marking a decrease of 11.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 2.08. The value appears to be declining and may need further review. It has decreased from 2.38 (Dec 2024) to 2.08, marking a decrease of 0.30.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: May 15, 2025, 6:11 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,324 | 1,515 | 1,593 | 1,683 | 1,672 | 1,814 | 1,711 | 1,909 | 2,196 | 2,486 | 2,757 | 2,847 |
| Expenses | 1,170 | 1,350 | 1,370 | 1,428 | 1,415 | 1,532 | 1,460 | 1,594 | 1,948 | 2,170 | 2,277 | 2,347 |
| Operating Profit | 154 | 164 | 223 | 255 | 257 | 282 | 251 | 315 | 248 | 316 | 480 | 500 |
| OPM % | 12% | 11% | 14% | 15% | 15% | 16% | 15% | 16% | 11% | 13% | 17% | 18% |
| Other Income | 8 | 6 | 13 | 10 | 62 | 27 | 16 | -5 | 19 | 47 | 54 | 51 |
| Interest | 55 | 14 | 62 | 56 | 48 | 35 | 33 | 19 | 12 | 13 | 5 | 6 |
| Depreciation | 24 | 33 | 31 | 30 | 31 | 31 | 53 | 56 | 58 | 50 | 50 | 56 |
| Profit before tax | 82 | 125 | 143 | 179 | 241 | 243 | 182 | 235 | 197 | 299 | 479 | 489 |
| Tax % | 1% | 3% | 48% | -14% | 26% | 19% | 10% | 19% | 19% | 20% | 23% | 24% |
| Net Profit | 81 | 121 | 74 | 204 | 179 | 198 | 163 | 191 | 159 | 240 | 369 | 370 |
| EPS in Rs | 2.25 | 3.35 | 2.16 | 5.73 | 5.12 | 5.59 | 4.64 | 5.43 | 4.41 | 6.53 | 10.06 | 10.09 |
| Dividend Payout % | 67% | 60% | 116% | 52% | 5% | 54% | 65% | 74% | 57% | 46% | 35% | 35% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 49.38% | -38.84% | 175.68% | -12.25% | 10.61% | -17.68% | 17.18% | -16.75% | 50.94% | 53.75% | 0.27% |
| Change in YoY Net Profit Growth (%) | 0.00% | -88.23% | 214.52% | -187.93% | 22.87% | -28.29% | 34.85% | -33.93% | 67.70% | 2.81% | -53.48% |
Jyothy Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 16% |
| 3 Years: | 32% |
| TTM: | 3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 19% |
| 3 Years: | 21% |
| 1 Year: | -39% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 17% |
| 3 Years: | 18% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 8:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:30 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 37 | 37 | 37 | 37 | 37 | 37 | 37 |
| Reserves | 716 | 762 | 883 | 1,071 | 1,126 | 1,290 | 1,192 | 1,392 | 1,407 | 1,512 | 1,772 | 2,013 |
| Borrowings | 534 | 569 | 451 | 498 | 544 | 281 | 285 | 117 | 171 | 47 | 51 | 61 |
| Other Liabilities | 386 | 468 | 417 | 266 | 291 | 335 | 323 | 410 | 408 | 466 | 542 | 580 |
| Total Liabilities | 1,654 | 1,817 | 1,770 | 1,853 | 1,979 | 1,942 | 1,836 | 1,956 | 2,023 | 2,062 | 2,401 | 2,691 |
| Fixed Assets | 1,094 | 1,074 | 1,068 | 1,097 | 1,091 | 1,101 | 1,149 | 1,147 | 1,122 | 1,116 | 1,125 | 1,141 |
| CWIP | 4 | 16 | 8 | 9 | 15 | 14 | 24 | 10 | 8 | 15 | 13 | 22 |
| Investments | 61 | 194 | 86 | 28 | 113 | 104 | 0 | 0 | 0 | 0 | 192 | 456 |
| Other Assets | 494 | 533 | 608 | 719 | 760 | 723 | 662 | 799 | 893 | 930 | 1,071 | 1,071 |
| Total Assets | 1,654 | 1,817 | 1,770 | 1,853 | 1,979 | 1,942 | 1,836 | 1,956 | 2,023 | 2,062 | 2,401 | 2,691 |
Below is a detailed analysis of the balance sheet data for Jyothy Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 37.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 37.00 Cr..
- For Reserves, as of Mar 2025, the value is 2,013.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,772.00 Cr. (Mar 2024) to 2,013.00 Cr., marking an increase of 241.00 Cr..
- For Borrowings, as of Mar 2025, the value is 61.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 51.00 Cr. (Mar 2024) to 61.00 Cr., marking an increase of 10.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 580.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 542.00 Cr. (Mar 2024) to 580.00 Cr., marking an increase of 38.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,691.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,401.00 Cr. (Mar 2024) to 2,691.00 Cr., marking an increase of 290.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1,141.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,125.00 Cr. (Mar 2024) to 1,141.00 Cr., marking an increase of 16.00 Cr..
- For CWIP, as of Mar 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2024) to 22.00 Cr., marking an increase of 9.00 Cr..
- For Investments, as of Mar 2025, the value is 456.00 Cr.. The value appears strong and on an upward trend. It has increased from 192.00 Cr. (Mar 2024) to 456.00 Cr., marking an increase of 264.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,071.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1,071.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,691.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,401.00 Cr. (Mar 2024) to 2,691.00 Cr., marking an increase of 290.00 Cr..
Notably, the Reserves (2,013.00 Cr.) exceed the Borrowings (61.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -380.00 | -405.00 | -228.00 | -243.00 | -287.00 | 1.00 | -34.00 | 198.00 | 77.00 | 269.00 | 429.00 | 439.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 18 | 14 | 22 | 25 | 35 | 31 | 26 | 18 | 24 | 20 | 27 | 35 |
| Inventory Days | 91 | 87 | 81 | 80 | 79 | 76 | 91 | 101 | 85 | 77 | 74 | 84 |
| Days Payable | 59 | 62 | 70 | 61 | 63 | 67 | 53 | 69 | 67 | 55 | 72 | 75 |
| Cash Conversion Cycle | 51 | 39 | 32 | 45 | 51 | 40 | 65 | 49 | 41 | 42 | 29 | 45 |
| Working Capital Days | 16 | -32 | -114 | -85 | -87 | -33 | -27 | -8 | -1 | 13 | 40 | 39 |
| ROCE % | 11% | 10% | 15% | 16% | 15% | 17% | 14% | 18% | 13% | 18% | 27% | 25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 9,798,362 | 0.87 | 528.92 | 9,798,362 | 2025-04-22 17:25:29 | 0% |
| Franklin India Flexi Cap Fund | 4,112,112 | 1.24 | 221.97 | 4,112,112 | 2025-04-22 17:25:29 | 0% |
| Franklin India Smaller Companies Fund | 3,516,504 | 1.32 | 189.82 | 3,516,504 | 2025-04-22 02:06:43 | 0% |
| Axis Small Cap Fund | 2,803,873 | 0.64 | 151.35 | 2,803,873 | 2025-04-22 17:25:29 | 0% |
| Canara Robeco Small Cap Fund | 2,521,750 | 1.11 | 136.12 | 2,521,750 | 2025-04-22 17:25:29 | 0% |
| Canara Robeco Flexi Cap Fund | 2,211,183 | 0.88 | 119.36 | 2,211,183 | 2025-04-22 17:25:29 | 0% |
| HSBC Small Cap Fund - Regular Plan | 2,184,602 | 0.69 | 117.92 | 2,184,602 | 2025-04-22 17:25:29 | 0% |
| Mirae Asset Great Consumer Fund | 2,023,943 | 2.58 | 109.25 | 2,023,943 | 2025-04-22 17:25:29 | 0% |
| Canara Robeco Equity Hybrid Fund | 1,795,000 | 0.9 | 99.96 | 1,795,000 | 2025-04-22 17:25:29 | 0% |
| Canara Robeco ELSS Tax Saver Fund | 1,756,100 | 1.05 | 94.79 | 1,756,100 | 2025-04-22 17:25:29 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 10.09 | 10.06 | 6.53 | 4.41 | 5.43 |
| Diluted EPS (Rs.) | 10.09 | 10.06 | 6.53 | 4.41 | 5.43 |
| Cash EPS (Rs.) | 11.62 | 11.42 | 7.89 | 5.92 | 6.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 55.81 | 49.30 | 42.24 | 38.20 | 37.87 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 55.81 | 49.30 | 42.24 | 38.20 | 37.87 |
| Revenue From Operations / Share (Rs.) | 77.53 | 75.08 | 67.70 | 59.82 | 51.99 |
| PBDIT / Share (Rs.) | 15.12 | 14.53 | 9.68 | 7.27 | 9.07 |
| PBIT / Share (Rs.) | 13.59 | 13.17 | 8.31 | 5.68 | 7.55 |
| PBT / Share (Rs.) | 13.31 | 13.04 | 8.15 | 5.36 | 6.39 |
| Net Profit / Share (Rs.) | 10.09 | 10.06 | 6.53 | 4.33 | 5.19 |
| NP After MI And SOA / Share (Rs.) | 10.09 | 10.06 | 6.53 | 4.41 | 5.43 |
| PBDIT Margin (%) | 19.50 | 19.35 | 14.29 | 12.15 | 17.44 |
| PBIT Margin (%) | 17.52 | 17.54 | 12.27 | 9.50 | 14.52 |
| PBT Margin (%) | 17.16 | 17.36 | 12.03 | 8.96 | 12.29 |
| Net Profit Margin (%) | 13.00 | 13.39 | 9.64 | 7.24 | 9.98 |
| NP After MI And SOA Margin (%) | 13.01 | 13.40 | 9.64 | 7.37 | 10.44 |
| Return on Networth / Equity (%) | 18.07 | 20.43 | 15.47 | 11.22 | 13.96 |
| Return on Capital Employeed (%) | 22.89 | 25.18 | 18.44 | 13.89 | 18.69 |
| Return On Assets (%) | 13.76 | 15.38 | 11.62 | 8.00 | 10.19 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.08 | 0.08 |
| Asset Turnover Ratio (%) | 1.12 | 1.24 | 1.45 | 1.27 | 1.16 |
| Current Ratio (X) | 2.76 | 2.37 | 1.91 | 1.39 | 1.32 |
| Quick Ratio (X) | 2.12 | 1.78 | 1.16 | 0.81 | 0.73 |
| Inventory Turnover Ratio (X) | 9.31 | 4.25 | 4.32 | 3.81 | 3.18 |
| Dividend Payout Ratio (NP) (%) | 34.69 | 29.81 | 38.29 | 90.68 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 30.12 | 26.26 | 31.67 | 66.72 | 0.00 |
| Earning Retention Ratio (%) | 65.31 | 70.19 | 61.71 | 9.32 | 0.00 |
| Cash Earning Retention Ratio (%) | 69.88 | 73.74 | 68.33 | 33.28 | 0.00 |
| Interest Coverage Ratio (X) | 93.62 | 112.80 | 27.15 | 22.61 | 17.31 |
| Interest Coverage Ratio (Post Tax) (X) | 64.18 | 79.08 | 18.78 | 14.48 | 12.13 |
| Enterprise Value (Cr.) | 11925.68 | 15977.96 | 6732.28 | 5292.85 | 4910.52 |
| EV / Net Operating Revenue (X) | 4.19 | 5.80 | 2.71 | 2.41 | 2.57 |
| EV / EBITDA (X) | 21.48 | 29.95 | 18.94 | 19.83 | 14.75 |
| MarketCap / Net Operating Revenue (X) | 4.24 | 5.86 | 2.82 | 2.47 | 2.63 |
| Retention Ratios (%) | 65.30 | 70.18 | 61.70 | 9.31 | 0.00 |
| Price / BV (X) | 5.89 | 8.93 | 4.53 | 3.75 | 3.52 |
| Price / Net Operating Revenue (X) | 4.24 | 5.86 | 2.82 | 2.47 | 2.63 |
| EarningsYield | 0.03 | 0.02 | 0.03 | 0.02 | 0.03 |
After reviewing the key financial ratios for Jyothy Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.62. This value is within the healthy range. It has increased from 11.42 (Mar 24) to 11.62, marking an increase of 0.20.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 55.81. It has increased from 49.30 (Mar 24) to 55.81, marking an increase of 6.51.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 55.81. It has increased from 49.30 (Mar 24) to 55.81, marking an increase of 6.51.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 77.53. It has increased from 75.08 (Mar 24) to 77.53, marking an increase of 2.45.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 15.12. This value is within the healthy range. It has increased from 14.53 (Mar 24) to 15.12, marking an increase of 0.59.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.59. This value is within the healthy range. It has increased from 13.17 (Mar 24) to 13.59, marking an increase of 0.42.
- For PBT / Share (Rs.), as of Mar 25, the value is 13.31. This value is within the healthy range. It has increased from 13.04 (Mar 24) to 13.31, marking an increase of 0.27.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
- For PBDIT Margin (%), as of Mar 25, the value is 19.50. This value is within the healthy range. It has increased from 19.35 (Mar 24) to 19.50, marking an increase of 0.15.
- For PBIT Margin (%), as of Mar 25, the value is 17.52. This value is within the healthy range. It has decreased from 17.54 (Mar 24) to 17.52, marking a decrease of 0.02.
- For PBT Margin (%), as of Mar 25, the value is 17.16. This value is within the healthy range. It has decreased from 17.36 (Mar 24) to 17.16, marking a decrease of 0.20.
- For Net Profit Margin (%), as of Mar 25, the value is 13.00. This value exceeds the healthy maximum of 10. It has decreased from 13.39 (Mar 24) to 13.00, marking a decrease of 0.39.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.01. This value is within the healthy range. It has decreased from 13.40 (Mar 24) to 13.01, marking a decrease of 0.39.
- For Return on Networth / Equity (%), as of Mar 25, the value is 18.07. This value is within the healthy range. It has decreased from 20.43 (Mar 24) to 18.07, marking a decrease of 2.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 22.89. This value is within the healthy range. It has decreased from 25.18 (Mar 24) to 22.89, marking a decrease of 2.29.
- For Return On Assets (%), as of Mar 25, the value is 13.76. This value is within the healthy range. It has decreased from 15.38 (Mar 24) to 13.76, marking a decrease of 1.62.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.12. It has decreased from 1.24 (Mar 24) to 1.12, marking a decrease of 0.12.
- For Current Ratio (X), as of Mar 25, the value is 2.76. This value is within the healthy range. It has increased from 2.37 (Mar 24) to 2.76, marking an increase of 0.39.
- For Quick Ratio (X), as of Mar 25, the value is 2.12. This value exceeds the healthy maximum of 2. It has increased from 1.78 (Mar 24) to 2.12, marking an increase of 0.34.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.31. This value exceeds the healthy maximum of 8. It has increased from 4.25 (Mar 24) to 9.31, marking an increase of 5.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 34.69. This value is within the healthy range. It has increased from 29.81 (Mar 24) to 34.69, marking an increase of 4.88.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 30.12. This value is within the healthy range. It has increased from 26.26 (Mar 24) to 30.12, marking an increase of 3.86.
- For Earning Retention Ratio (%), as of Mar 25, the value is 65.31. This value is within the healthy range. It has decreased from 70.19 (Mar 24) to 65.31, marking a decrease of 4.88.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 69.88. This value is within the healthy range. It has decreased from 73.74 (Mar 24) to 69.88, marking a decrease of 3.86.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 93.62. This value is within the healthy range. It has decreased from 112.80 (Mar 24) to 93.62, marking a decrease of 19.18.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 64.18. This value is within the healthy range. It has decreased from 79.08 (Mar 24) to 64.18, marking a decrease of 14.90.
- For Enterprise Value (Cr.), as of Mar 25, the value is 11,925.68. It has decreased from 15,977.96 (Mar 24) to 11,925.68, marking a decrease of 4,052.28.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.19. This value exceeds the healthy maximum of 3. It has decreased from 5.80 (Mar 24) to 4.19, marking a decrease of 1.61.
- For EV / EBITDA (X), as of Mar 25, the value is 21.48. This value exceeds the healthy maximum of 15. It has decreased from 29.95 (Mar 24) to 21.48, marking a decrease of 8.47.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.24. This value exceeds the healthy maximum of 3. It has decreased from 5.86 (Mar 24) to 4.24, marking a decrease of 1.62.
- For Retention Ratios (%), as of Mar 25, the value is 65.30. This value is within the healthy range. It has decreased from 70.18 (Mar 24) to 65.30, marking a decrease of 4.88.
- For Price / BV (X), as of Mar 25, the value is 5.89. This value exceeds the healthy maximum of 3. It has decreased from 8.93 (Mar 24) to 5.89, marking a decrease of 3.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.24. This value exceeds the healthy maximum of 3. It has decreased from 5.86 (Mar 24) to 4.24, marking a decrease of 1.62.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jyothy Labs Ltd:
- Net Profit Margin: 13%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 22.89% (Industry Average ROCE: 29.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 18.07% (Industry Average ROE: 22.42%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 64.18
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 29.1 (Industry average Stock P/E: 46.43)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13%
Fundamental Analysis of Jyothy Labs Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Personal Care | Ujala House, Ramkrishna Mandir Road, Mumbai Maharashtra 400059 | info@jyothy.com http://www.jyothylabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. M P Ramachandran | Chairman Emeritus |
| Mr. R Lakshminarayanan | Chairman & Ind.Director |
| Ms. M R Jyothy | Managing Director |
| Ms. M R Deepthi | Whole Time Director |
| Mr. Aditya Sapru | Independent Director |
| Mr. Nilesh Mehta | Independent Director |
| Ms. Bhumika Batra | Independent Director |
Jyothy Labs Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹431.40 |
| Previous Day | ₹447.70 |
FAQ
What is the intrinsic value of Jyothy Labs Ltd?
Jyothy Labs Ltd's intrinsic value (as of 05 December 2025) is 249.80 which is 13.86% lower the current market price of 290.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 10,649 Cr. market cap, FY2025-2026 high/low of 433/268, reserves of ₹2,013 Cr, and liabilities of 2,691 Cr.
What is the Market Cap of Jyothy Labs Ltd?
The Market Cap of Jyothy Labs Ltd is 10,649 Cr..
What is the current Stock Price of Jyothy Labs Ltd as on 05 December 2025?
The current stock price of Jyothy Labs Ltd as on 05 December 2025 is 290.
What is the High / Low of Jyothy Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Jyothy Labs Ltd stocks is 433/268.
What is the Stock P/E of Jyothy Labs Ltd?
The Stock P/E of Jyothy Labs Ltd is 29.1.
What is the Book Value of Jyothy Labs Ltd?
The Book Value of Jyothy Labs Ltd is 55.8.
What is the Dividend Yield of Jyothy Labs Ltd?
The Dividend Yield of Jyothy Labs Ltd is 1.21 %.
What is the ROCE of Jyothy Labs Ltd?
The ROCE of Jyothy Labs Ltd is 24.6 %.
What is the ROE of Jyothy Labs Ltd?
The ROE of Jyothy Labs Ltd is 19.0 %.
What is the Face Value of Jyothy Labs Ltd?
The Face Value of Jyothy Labs Ltd is 1.00.